Plasma cell myeloma+1
Not recruitingStudy Comparing Ciltacabtagene Autoleucel with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed and Lenalidomide-Refractory Multiple Myeloma
Study Comparing Ciltacabtagene Autoleucel with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed and Lenalidomide-Refractory Multiple Myeloma
- Disease:Plasma cell myelomaPlasma cell myeloma refractory
- Substances:BortezomibCyclophosphamide+5
Poland- Participants:18–64 years · 65+ years
- Substances:Bortezomib
- Sponsor:Janssen Cilag International









